Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03989466
Recruitment Status : Not yet recruiting
First Posted : June 18, 2019
Last Update Posted : June 18, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Not yet recruiting
  Estimated Primary Completion Date : December 31, 2021
  Estimated Study Completion Date : December 31, 2022